Animal models are still widely used to assess the efficacy or safety of new pharmaceutical products. Since their limitations in predicting actions of drugs in humans are becoming more and more apparent, there is an urgent need to revisit the use of animals in pharmaceutical research. Herein, we review how the Innovative Medicines Initiative (IMI), the largest public-private partnership in the life sciences, is reducing, refining and replacing the use of animals in the context of its global mission, namely, to boost research and the development of new medicines across the European Union.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/026119291204000603 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!